World journal of surgery · 2025
Quality of Life After Parathyroidectomy in Chronic Kidney Disease-Related Hyperparathyroidism: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alves Filho Wellington, D'Elboux Guimarães Brescia Marília, Magnabosco Felipe Ferraz, Catafesta das Neves Murilo, Arap Sergio Samir, Santos Rodrigo Oliveira, de Almeida Mota Ramalho Janaína, Luiz de Menezes Montenegro Fabio, Studart da Fonseca Marcio Ribeiro
Аннотация
BACKGROUND: Secondary and tertiary hyperparathyroidism (SHPT and THPT) are frequent complications of chronic kidney disease and kidney transplantation, often impairing quality of life (QoL) through bone pain, fatigue, and pruritus. Parathyroidectomy is the definitive treatment for refractory cases, yet its impact on patient-reported QoL outcomes remains uncertain.
METHODS: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines (PROSPERO CRD42025108038). Nine studies (n = 675) with validated QoL assessments and ≥ 6 months of follow-up were included. QoL was measured using SF-36, KDQOL, and Pasieka's parathyroid assessment of symptoms (PAS). Standardized mean differences (SMDs) were calculated, with analyses of physical (PCS) and mental (MCS) component summary scores. Meta-regression evaluated preoperative parathyroid hormone (PTH), calcium, and phosphorus as predictors of QoL change.
RESULTS: Parathyroidectomy significantly improved global QoL (Hedges' g = 1.05; 95% CI: 0.42-1.69; p = 0.0011), PCS (SMD = 0.85; 95% CI: 0.32-1.37; p < 0.001), and MCS (SMD = 0.40; 95% CI: 0.11-0.69; p = 0.001). PAS scores also improved (SMD = -1.66; 95% CI: -2.72 to -0.60; p = 0.004). Preoperative PTH, calcium, and phosphorus were not associated with postoperative QoL gains (p = 0.71, 0.54, 0.47). Both subtotal and total parathyroidectomy provided comparable benefits (p = 0.76).
CONCLUSION: Parathyroidectomy leads to meaningful QoL improvements in CKD-related hyperparathyroidism, regardless of surgical technique. Baseline biochemical markers do not predict postoperative gains. Standardized, long-term studies of patient-reported outcomes are needed to guide surgical decision-making.
METHODS: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines (PROSPERO CRD42025108038). Nine studies (n = 675) with validated QoL assessments and ≥ 6 months of follow-up were included. QoL was measured using SF-36, KDQOL, and Pasieka's parathyroid assessment of symptoms (PAS). Standardized mean differences (SMDs) were calculated, with analyses of physical (PCS) and mental (MCS) component summary scores. Meta-regression evaluated preoperative parathyroid hormone (PTH), calcium, and phosphorus as predictors of QoL change.
RESULTS: Parathyroidectomy significantly improved global QoL (Hedges' g = 1.05; 95% CI: 0.42-1.69; p = 0.0011), PCS (SMD = 0.85; 95% CI: 0.32-1.37; p < 0.001), and MCS (SMD = 0.40; 95% CI: 0.11-0.69; p = 0.001). PAS scores also improved (SMD = -1.66; 95% CI: -2.72 to -0.60; p = 0.004). Preoperative PTH, calcium, and phosphorus were not associated with postoperative QoL gains (p = 0.71, 0.54, 0.47). Both subtotal and total parathyroidectomy provided comparable benefits (p = 0.76).
CONCLUSION: Parathyroidectomy leads to meaningful QoL improvements in CKD-related hyperparathyroidism, regardless of surgical technique. Baseline biochemical markers do not predict postoperative gains. Standardized, long-term studies of patient-reported outcomes are needed to guide surgical decision-making.